Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.
- DOI
- 10.1038/s41591-022-01861-9
- Published
- 2022 Jul
- Container
- Nature medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-022-01861-9,
title = {Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.},
author = {Harrison SA and Manghi FP and Smith WB and Alpenidze D and Aizenberg D and Klarenbeek N and Chen CY and Zuckerman E and Ravussin E and Charatcharoenwitthaya P and Cheng PN and Katchman H and Klein S and Ben-Ari Z and Mendonza AE and Zhang Y and Martic M and Ma S and Kao S and Tanner S and Pachori A and Badman MK and He Y and Ukomadu C and Sicard E},
year = {2022},
journal = {Nature medicine},
doi = {10.1038/s41591-022-01861-9},
url = {https://doi.org/10.1038/s41591-022-01861-9}
}RIS
TY - JOUR TI - Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. AU - Harrison SA AU - Manghi FP AU - Smith WB AU - Alpenidze D AU - Aizenberg D AU - Klarenbeek N AU - Chen CY AU - Zuckerman E AU - Ravussin E AU - Charatcharoenwitthaya P AU - Cheng PN AU - Katchman H AU - Klein S AU - Ben-Ari Z AU - Mendonza AE AU - Zhang Y AU - Martic M AU - Ma S AU - Kao S AU - Tanner S AU - Pachori A AU - Badman MK AU - He Y AU - Ukomadu C AU - Sicard E PY - 2022 JO - Nature medicine DO - 10.1038/s41591-022-01861-9 UR - https://doi.org/10.1038/s41591-022-01861-9 ER -
APA
SA, H., FP, M., WB, S., D, A., D, A., N, K., CY, C., E, Z., E, R., P, C., PN, C., H, K., S, K., Z, B., AE, M., Y, Z., M, M., S, M., S, K., S, T., A, P., MK, B., Y, H., C, U., & E, S. (2022). Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.. Nature medicine. https://doi.org/10.1038/s41591-022-01861-9
Source records
- pubmed · retrieved 2026-09-26T22:13:06.108Z